Notwithstanding promising clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial opposition from managed care entities. The insurers are often erecting obstacles to coverage, like high cost restrictions and approval processes that hinder user availability. Market beli… Read More